Phase II Study of Genasense (Bcl-2 Antisense) Combined With Mylotarg (Gemtuzumab Ozogamicin) in Elderly Patients With Relapsed Acute Myeloid Leukemia.

Trial Profile

Phase II Study of Genasense (Bcl-2 Antisense) Combined With Mylotarg (Gemtuzumab Ozogamicin) in Elderly Patients With Relapsed Acute Myeloid Leukemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jan 2014

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary) ; Oblimersen (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Genta
  • Most Recent Events

    • 10 Jan 2014 Last checked against ClinicalTrials.gov record.
    • 10 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 10 Jan 2014 Planned number of patients changed from 20 to 100 as ClinicalTrials.gov reports planned patient no 20 -100, so considered highest number
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top